Exchange: NASDAQ·Updated 07:58 PM EST
KYMR logo

KYMR Kymera Therapeutics Inc

$115.31
$4.08
(3.42%)
Today
Closed $115.31
$8.79
(7.62%)
After Hours
Reported EarningsOct 29
Mkt Cap$9.84B
Vol1.28M

About KYMR

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
37

Bearish Sentiment

How do you feel about KYMR?

Seabass1459
$KYMR Nice 10% er. To hold through earnings or not is the question....... hmmmmmm .. maybe half off the table? The earnings ive been watching seem to favor the downside this week regardless of results.
2
MikeyNJ
$KYMR KT-621 data to be presented Monday AM. I am confident it will be impressive. A couple months ago I sold some January $195 calls against some shares thinking I was ingenious collecting $11.15. I don't lose on those unless the stock trades north of $206. Guess that will be a good problem to have.
1
MooseG
$KYMR up 25$ in a month. Trading like data will be good. Just sell the the company already.
1
Rayvio_News_Filter
$KYMR 🏥 The FDA cleared Kayak Therapeutics' IND application for KT-300, an oral TRIM7 inhibitor for RAS-driven cancers, to enable a Phase 1 first-in-human study. Selected from hundreds of headlines
1
Seabass1459
$KYMR 80 shares @ 110.9 avg still holding. Not sure where I trim this has been unstoppabable, I see positive MACD crossover on the weekly chart which I like a lot. if the overall market doesnt rollover here I see momentum continuing! Suspect positive data end of year from my readings.
1
MarkNewtonCMT
$KYMR Kymera Therapeutics- I continue to find many HC stocks far more attractive than many within Tech these days, and scanning #IBD "Breaking out Today" list which we're also building w/ Fundstrat AI, gives me the ability to compare what is showing to what i show Beautiful long-term base breakouts are happening across sub-sectors within Healthcare. While i do anticipate Tech can lead the bounce into next week, it's got some "wood to chop" to say the least Elections can be a positive force for Partisanship lessening, but they're not the market clearing event many expect if Rates haven't officially peaked yet #IBDPartner
1
MikeyNJ
$KYMR I thought I was a genius selling the January $195 calls for $11. This is behaving as if it will be much higher by then. Amazing!
1
shoc24
$KYMR is estimated to report earnings tomorrow before the open. I used Stock Meadow’s earnings dashboard to review its history: KYMR has beaten EPS estimates in 4 of its last 8 reports.
1
VISIUM
$KYMR I'm betting 98% chose to enroll in the open label extension because they all assumed they got the placebo and now want to see if the drug actually works. lol
Quantumup
Oppenheimer⬆️ $KYMR's PT to $140, reiterated Outperform following early encouraging KT-579 results and sees pot'l 40%⬆️for model on +VE BROADEN2/KT-621 results. [GSK AUPH AZN RHHBY BIIB NVS BMY ABBV [REGN - SNY CRVS APGE/ABBV NKTR CLDX]] Oppenheimer said in its note: On Thursday KYMR reported convincing results from the KT-579 HV study, along with 3Q financial results. KT-579 demonstrated potent degradation of IRF-5 with doses levels 2-6 all exhibiting ≥90% degradation of the target. Management expects to go into a quiet period in the coming days with the evaluation of the BROADEN2 dataset to begin shortly. Top-line results for this key dataset in AD are on track for release before year-end. We increase our PT from $125 to $140 following these encouraging early results for '579, and see a potential further ~40% upside to our model on positive BROADEN2 results. The company ended 3Q with cash of $1.6B anticipated to support operations into 2029.
shoc24
$KYMR reported earnings before the open: GAAP EPS of −$1.32 vs. −$1.26 estimated, a miss of 4.8%. I used Stock Meadow to review the results.
filecrux
$KYMR Can KT-579's ≥90% IRF5 knockdown in healthy volunteers carry over to lupus patients? 🏢 Kymera Therapeutics, which makes oral protein-degrader drugs for immune diseases and was valued at about $10.19B at $122.51 a share at 16:00 ET on October 28, 2026, reported the first human results for its oral IRF5 degrader KT-579 alongside its Q3 numbers 📈 In the trial's multiple-dose part, KT-579 cut IRF5 in blood by a median of at least 90% across several dose levels, the effect stopped increasing by dose level 3, and skin showed similar reductions ⚠️ These results come from healthy volunteers and lab-stimulated blood tests rather than lupus patients, and the next step is a roughly 30-patient, 16-week biomarker study rather than an efficacy trial 📅 Next: KT-579 preclinical lupus data at ACR, November 6-11, 2026; the LUMORA lupus trial is planned to start by early 2027 Source: GlobeNewswire release + SEC 8-K, Oct 29
StocktwitsEarnings
$KYMR Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.32 down -40.43% YoY • Reported revenue of $0M
Merlintrader
$KYMR — Morgan Stanley Overweight, price target $146 (from $135). Information only — not investment advice. More details in our hub.

Advertisement|Remove ads.